Over the past 12 months, 10 insiders at ALNYLAM PHARMACEUTICALS, INC. filed 412 open-market SEC Form 4 transactions on ALNY: 0 purchases worth $0 and 412 sales worth $89.1M. Insiders have been net sellers over this period. The most recent filing was on Jun 1, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 1, 26 | Pyott David E I | SELL | 1.2K | $302.65 | $366K |
| Apr 6, 26 | Melissa McLaughlinChief Human Resources Officer | SELL | 909 | $333.94 | $300K |
| Apr 2, 26 | Melissa McLaughlinChief Human Resources Officer | SELL | 359 | $325.49 | $114K |
| Mar 5, 26 | Kevin Joseph FitzgeraldCSO & EVP, Head of Research | SELL | 233 | $326.24 | $75K |
| Mar 5, 26 | Pushkal GargEVP Chief R&D | SELL | 740 | $326.08 | $239K |
| Mar 4, 26 | Kevin Joseph FitzgeraldCSO & EVP, Head of Research | SELL | 210 | $325.67 | $68K |
| Mar 4, 26 | Pushkal GargEVP Chief R&D | SELL | 767 | $325.67 | $248K |
| Mar 4, 26 | Yvonne GreenstreetChief Executive Officer | SELL | 973 | $325.67 | $315K |
| Mar 4, 26 | Jeffrey Poulton V.EVP, Chief Financial Officer | SELL | 818 | $325.67 | $265K |
| Mar 4, 26 | Tolga TangulerEVP, Chief Commercial Officer | SELL | 767 | $325.67 | $248K |
| Mar 3, 26 | Kevin Joseph FitzgeraldCSO & EVP, Head of Research | SELL | 722 | $321.58 | $231K |
| Mar 3, 26 | Pushkal GargEVP Chief R&D | SELL | 640 | $321.50 | $205K |
| Mar 2, 26 | Kevin Joseph FitzgeraldCSO & EVP, Head of Research | SELL | 392 | $332.64 | $128K |
| Mar 2, 26 | Pushkal GargEVP Chief R&D | SELL | 421 | $332.64 | $138K |
| Mar 2, 26 | Yvonne GreenstreetChief Executive Officer | SELL | 1.7K | $332.64 | $545K |
| Mar 2, 26 | Jeffrey Poulton V.EVP, Chief Financial Officer | SELL | 541 | $332.64 | $177K |
| Mar 2, 26 | Tolga TangulerEVP, Chief Commercial Officer | SELL | 392 | $332.64 | $128K |
| Feb 27, 26 | Pushkal GargEVP Chief R&D | SELL | 2.3K | $334.39 | $747K |
| Feb 17, 26 | Kevin Joseph FitzgeraldCSO & EVP, Head of Research | SELL | 2.0K | $331.96 | $678K |
| Feb 13, 26 | Kevin Joseph FitzgeraldCSO & EVP, Head of Research | SELL | 2.0K | $310.08 | $607K |
| Feb 13, 26 | Pushkal GargEVP Chief R&D | SELL | 2.2K | $310.08 | $695K |
| Feb 13, 26 | Yvonne GreenstreetChief Executive Officer | SELL | 7.0K | $310.08 | $2.2M |
| Feb 13, 26 | Jeffrey Poulton V.EVP, Chief Financial Officer | SELL | 2.2K | $310.08 | $695K |
| Feb 13, 26 | Tolga TangulerEVP, Chief Commercial Officer | SELL | 2.0K | $310.08 | $607K |
| Jan 13, 26 | Kevin Joseph FitzgeraldCSO & EVP, Head of Research | SELL | 644 | $374.33 | $238K |
| Jan 12, 26 | Kevin Joseph FitzgeraldCSO & EVP, Head of Research | SELL | 220 | $377.82 | $80K |
| Jan 12, 26 | Pushkal GargEVP Chief R&D | SELL | 220 | $377.82 | $80K |
| Jan 12, 26 | Yvonne GreenstreetChief Executive Officer | SELL | 1.4K | $377.82 | $510K |
| Jan 12, 26 | Jeffrey Poulton V.EVP, Chief Financial Officer | SELL | 405 | $377.82 | $148K |
| Jan 12, 26 | Tolga TangulerEVP, Chief Commercial Officer | SELL | 220 | $377.82 | $80K |
| Nov 17, 25 | Kevin Joseph FitzgeraldCSO & EVP, Head of Research | SELL | 8.2K | $463.08 | $3.7M |
| Nov 13, 25 | Yvonne GreenstreetChief Executive Officer | SELL | 2.2K | $456.03 | $1000K |
| Nov 12, 25 | Yvonne GreenstreetChief Executive Officer | SELL | 3.4K | $458.42 | $1.6M |
| Oct 3, 25 | Pushkal GargEVP Chief R&D | SELL | 898 | $454.37 | $406K |
| Oct 2, 25 | Kevin Joseph FitzgeraldCSO & EVP, Head of Research | SELL | 555 | $457.64 | $251K |
| Oct 2, 25 | Pushkal GargEVP Chief R&D | SELL | 668 | $457.64 | $302K |
| Oct 2, 25 | Yvonne GreenstreetChief Executive Officer | SELL | 2.0K | $457.64 | $919K |
| Oct 2, 25 | Jeffrey Poulton V.EVP, Chief Financial Officer | SELL | 869 | $457.64 | $393K |
| Oct 2, 25 | Tolga TangulerEVP, Chief Commercial Officer | SELL | 319 | $457.64 | $144K |
| Sep 9, 25 | Colleen F ReitanDirector | SELL | 2.3K | $480.98 | $1.1M |
| Aug 29, 25 | Tolga TangulerEVP, Chief Commercial Officer | SELL | 1.3K | $452.49 | $578K |
| Aug 19, 25 | Pushkal GargEVP Chief R&D | SELL | 338 | $461.74 | $155K |
| Aug 18, 25 | Michael W BonneyDirector | SELL | 11.3K | $450.00 | $5.1M |
| Aug 18, 25 | Kevin Joseph FitzgeraldCSO & EVP, Head of Research | SELL | 543 | $455.82 | $247K |
| Aug 18, 25 | Pushkal GargEVP Chief R&D | SELL | 543 | $455.82 | $247K |
| Aug 18, 25 | Yvonne GreenstreetChief Executive Officer | SELL | 2.7K | $455.82 | $1.2M |
| Aug 18, 25 | Jeffrey Poulton V.EVP, Chief Financial Officer | SELL | 886 | $455.82 | $402K |
| Aug 18, 25 | Tolga TangulerEVP, Chief Commercial Officer | SELL | 543 | $455.82 | $247K |
| Aug 14, 25 | Dennis A AusielloDirector | SELL | 7.7K | $442.66 | $3.3M |
| Jun 2, 25 | Yvonne GreenstreetChief Executive Officer | SELL | 19.3K | $306.00 | $5.9M |
Over the past 12 months, insiders at ALNYLAM PHARMACEUTICALS, INC. filed 0 open-market purchases worth $0 and 412 sales worth $89.1M on ALNY, which makes them net sellers over the period. The most recent Form 4 was filed on Jun 1, 26.
10 different insiders at ALNYLAM PHARMACEUTICALS, INC. filed open-market SEC Form 4 transactions on ALNY over the last 12 months.
InsiderTape plots every ALNY insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every ALNYLAM PHARMACEUTICALS, INC. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →